Infection Clinical Trial
Official title:
The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Intestinal Function Recovery and Infection in Neonates and Infants Undergoing Gastrointestinal Surgery: a Prospective, Randomised, Controlled Trial
Sixty neonates and infants will be enrolled and randomised into two groups of n=30 each .
For their surgical procedures, one group general (GA) anaesthesia the second group will
receive a combined general and epidural anaesthesia (CGEA).
Anaesthetic technique:
Patients in the GA group will be induced with intravenous propofol (2-4 mg.kg-1) and
fentanyl (2-4 µg.kg-1) and will receive rocuronium bromide (0.5 mg.kg-1) to facilitate
endotracheal intubation. Anaesthesia will be maintained with sevoflurane (2-3%) in an
air/oxygen mixture as well as intravenous fentanyl as required.
In the (CGEA) 0.5 ml.kg-1 of 0.25% bupivacaine will be injected into the epidural catheter,
followed by a continuous infusion of 0.1% bupivacaine at a rate of 0.2 mg.kg-1.hr-1 for up
to 48 hours postoperatively. Assessment of anaesthetic efficacy will be measured
Intraoperative care vital signs. And will continuously be monitored with a Datex AS/3
(Engestrom®, Helsinki, Finland) monitor.
The use of antibiotic prophylaxis will be determined by the degree of bowel contamination
during surgery, with the commonest regimen consisting of penicillin, gentamicin and
metronidazole will be administered. Antibiotics will be continued for 36-48 hours
postoperatively to prevent infection arising from the disturbed bowel flora.
Postoperative care, following surgery, will be conducted. The feeding volume will be
increased in steps as long as the volume of regurgitated fluid will be less than 20% of the
administered breast milk or formula volume. Full feeding will define as oral tolerance of at
least 80% of daily maintenance volume. In cases of abdominal distension or vomiting, feeding
will withheld until symptom resolution. The nasogastric tube will be removed on bowel
function restoration The CRIES score will be use to assess the severity and duration of
postoperative pain during the patients' NICU stay. If the CRIES score is ≥4, fentanyl will
be continuously intravenously infused in both study group. Fentanyl will be also
administered to CGEA patients who experienced pain despite a continuous epidural infusion at
1-5 µg.kg-1.h-1. The amount of fentanyl required for adequate postoperative pain relief will
be recorded in both groups.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | July 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 6 Months |
Eligibility |
Inclusion Criteria: - Neonates or infants requiring the following major intestinal procedures: duodenoduodenostomy or duodenojejunostomy for duodenal atresia, - ileocaecal resection for intestinal volvulus, - ileostomy or colostomy closure for congenital anorectal malformations, - corrective surgery for Hirschsprung's disease. emergent intestinal surgery. Exclusion Criteria: - The exclusion criteria are concurrent coagulopathies, - sepsis, - vertebral column malformations, - neurological disease, - immunocompromise with or without leukopenia, - intestinal necrotising enterocolitis. - Patients will be also excluded if they required exploratory laparotomy or or emergent intestinal surgery |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bnai Zion Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative intestinal function recovery for neonates and infants undergoing gastrointestinal surgery. Which anesthetic method be superior and favoured as normal practice general or combined general and epidural anesthesia. | The outcomes measured to determine recovery of intestinal function recovery: Time to first postoperative defecation measured in hours or days Duration of nasogastric feeding measured in hours or days Time to tolerance of full oral feeding measured in hours or days |
upto 20 days postoperative | |
Secondary | Rate and sort of postoperative infection | Surgical site infection (SSI) Remote site infection (RSI) |
upto 20 days postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |